Theravance Biopharma (TBPH)
(Real Time Quote from BATS)
$9.54 USD
-0.06 (-0.63%)
Updated May 7, 2024 02:38 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TBPH 9.54 -0.06(-0.63%)
Will TBPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Other News for TBPH
Fly Insider: Theravance Bio, Amgen among week's notable insider trades
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Theravance Biopharma Breaks Above 200-Day Moving Average - Bullish for TBPH
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers